瑞普生物股份有限公司 董事会薪酬与考核委员会工作细则 第一章 总则 第一条 瑞普生物股份有限公司（以下简称"公司"）为进一步建立健 全公司董事及高级管理人员的考核和薪酬管理制度，完善公司治理结构，根据《中华 人民共和国公司法》《上市公司独立董事管理办法》《上市公司治理准则》《深圳证券交 易所上市公司自律监管指引第2号——创业板上市公司规范运作》《瑞普生物股份有限公司 章程》（以下简称"《公司章程》"）等有关法律、法规、规范性文件的规定，公司特设 立董事会薪酬与考核委员会（以下简称"薪酬与考核委员会"），并制定本工作细则。 第二条 薪酬与考核委员会是董事会按照股东会决议设立的专门工作机构， 主要职责是：（1）研究董事与高级管理人员考核的标准，进行考核并提出建议； （2）研究和审查董事、高级管理人员的薪酬政策与方案。 第三条 本工作细则所称高级管理人员是指公司章程规定的高级管理人员。 第二章 人员组成 第四条 薪酬与考核委员会成员由三名董事组成，独立董事占多数。 第五条 薪酬与考核委员会委员由董事长、二分之一以上独立董事或者全体董 事的三分之一提名，并由董事会选举产生。 第六条 薪酬与考核委员会设召集人一名，负责 ...

瑞普生物股份有限公司 股东会议事规则 第一章 总 则 第一条 为规范公司行为，保证股东会依法行使职权，根据《中华人民共和 国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证 券法》"）、《上市公司治理准则》《深圳证券交易所创业板股票上市规则》《深圳 证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》等有关 法律、行政法规和规范性文件以及《瑞普生物股份有限公司章程》（以下简称"《公 司章程》"）的规定，制定本规则。 第二条 公司应当严格按照法律、行政法规、《公司章程》及本规则的相关 规定召开股东会，保证股东能够依法行使权利。 公司董事会应当切实履行职责，认真、按时组织股东会。公司全体董事应当 勤勉尽责，确保股东会正常召开和依法行使职权。 第三条 股东会是公司的权力机构，依法行使下列职权： （一）选举和更换董事，决定有关董事的报酬事项； （二）审议批准董事会的报告； （三）审议批准公司的利润分配方案和弥补亏损方案； （四）对公司增加或者减少注册资本作出决议； （五）对发行公司债券作出决议； （六）对公司合并、分立、解散、清算或者变更公司形式作出决议； （七）修改公司章 ...

二〇二五年十一月二十八日 瑞普生物股份有限公司（以下简称"公司"）于 2025 年 11 月 28 日召开了 第五届董事会第三十次（临时）会议，审议通过了《关于公司董事会换届选举暨 提名第六届董事会独立董事候选人的议案》，提名王凯先生为公司第六届董事会 独立董事候选人。 截至公司 2025 年第六次临时股东会通知发出日，王凯先生尚未取得深圳证 券交易所认可的独立董事资格证书。根据《上市公司独立董事管理办法》《深圳 证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》的相关 规定，王凯先生承诺如下："本人王凯尚未取得独立董事资格证书，承诺参加最 近一次独立董事培训并取得深圳证券交易所认可的独立董事资格证书。上市公司 瑞普生物股份有限公司（证券代码：300119）将公告本人的上述承诺。" 承诺人：王凯 瑞普生物股份有限公司 独立董事候选人关于参加最近一次独立董事培训 并取得独立董事资格证书的承诺 ...

Group 1: Shareholding Changes - The National Integrated Circuit Industry Investment Fund reduced its stake in Saiwei Electronics from 5.88% to 4.999986% by selling 6.4278 million shares, which is a decrease of 1% [1] - The fund previously reduced its holdings from 6.95% to 5.88% by selling 7.836718 million shares, also a decrease of 1% [1] - Jiangsu Boyun's shareholder, Blue Three Venture Capital, plans to reduce its stake by up to 1%, amounting to 971,300 shares [5] Group 2: Corporate Actions - Chenshan Technology is planning to issue A-shares to Hefei State Investment, which may lead to a change in company control, and the stock will be suspended from trading for up to 2 days [2] - Haichang New Materials intends to acquire 51% of Shenzhen Xinwei Communications for 234.6 million yuan, gaining control over the company [3] - Yuanli Co. plans to acquire 100% of Fujian Tongsheng New Materials for 470 million yuan, aiming to enhance its strategic layout in the silicon dioxide sector [4] Group 3: Share Buybacks and Increases - Mindray Medical's chairman, Li Xiting, plans to increase his stake in the company by 200 million yuan, having already purchased 152,340 shares at an average price of 196.862 yuan per share [6] Group 4: Product Approvals and Innovations - Ruipu Biotech received a new veterinary drug registration certificate for a tri-valent inactivated vaccine for cats, enhancing its competitive edge in the companion animal health sector [7] - Tianli Lithium Energy obtained two invention patents related to lithium-ion battery electrode materials, which may improve its innovation capabilities [7]

| 新兽药名称 | 研制单位 | 类别 | 新兽药注册证号 | | --- | --- | --- | --- | | 猫鼻气管炎、杯状病毒病、 | 瑞普生物股份有限公司、天津 | | | | 泛白细胞减少症三联灭活 | | | | | | 瑞普生物技术股份有限公司空 | | （2025）新兽药证字 | | 疫 苗 （ 株 RPVF0304 | | 三类 | | | | 港经济区分公司、瑞普（保定） | | 127 号 | | +RPVF0207 株 +RPVF0110 | | | | | | 生物药业有限公司 | | | | 株） | | | | 证券代码：300119 证券简称：瑞普生物 公告编号：2025-091 瑞普生物股份有限公司 关于取得新兽药注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 瑞普生物股份有限公司（以下简称"公司""瑞普生物"）自主研制的猫鼻 气管炎、杯状病毒病、泛白细胞减少症三联灭活疫苗（RPVF0304 株+RPVF0207 株+RPVF0110 株）于 2023 年 8 月 22 日通过农业农村部组织的应急评价， ...

Group 1 - The SW Agricultural, Forestry, Animal Husbandry, and Fishery industry outperformed the CSI 300 index, with an overall increase of 16.36% from January to November 2025, surpassing the index by approximately 3.18 percentage points [12][13][14] - All sub-sectors within the industry recorded positive returns, with significant increases in animal health (36.27%), fishery (35.22%), agricultural product processing (21.88%), feed (12.48%), breeding (11.53%), and planting (8.49%) [13] - Approximately 83% of stocks in the industry achieved positive returns, with around 5% of stocks increasing by over 100%, and 17% recording negative returns [14][17] Group 2 - The breeding industry is experiencing a gradual reduction in the number of breeding sows, with a current stock of 40.35 million heads, which is 1.1% lower than the previous year [23][24] - The price of live pigs has shown a downward trend in 2025, with an average price of 11.65 yuan/kg as of November 24, down 26% from the beginning of the year, but is expected to gradually recover in 2026 [26] - The profitability of pig farming has turned negative, with self-breeding losses at 135.9 yuan per head and external piglet purchases at 234.63 yuan per head, but a recovery is anticipated in 2026 [31] Group 3 - The meat chicken breeding sector faced challenges in profitability during 2025, with the average price of broiler chicks fluctuating and a significant decline in profitability [33][35] - The supply of yellow feathered chickens is expected to remain relatively abundant in 2026, with a high stock of breeding chickens [45][47] - The overall feed production in China is projected to continue its recovery, with a total production of 15.85 million tons in the first half of 2025, reflecting a year-on-year increase of 7.7% [50] Group 4 - The prices of feed raw materials such as corn and soybean meal have shown fluctuations, with corn prices recovering from a low of 2115.59 yuan/ton to around 2300.88 yuan/ton by late November 2025 [52][53] - The global supply of corn is expected to remain ample, with a projected production of 128.6 million tons for the 2025/26 season, indicating limited price recovery potential [55] - The overall market for pet food in China is anticipated to grow, with an increase in exports and a rising domestic market [38][40]

Core Viewpoint - The company, Reap Bio (300119.SZ), currently does not have a specific vaccine for the H5N5 avian influenza, but its existing H5+H7 vaccine theoretically offers good protection against the prevalent H5N5 strain due to its genetic components [1] Group 1 - The company and the domestic market currently lack a dedicated H5N5 avian influenza vaccine [1] - The H5N5 strain circulating abroad belongs to the clade 2.3.4.4b genetic branch, which is crucial for evaluating vaccine efficacy [1] - The existing H5+H7 vaccine contains components of the clade 2.3.4.4b strain, suggesting it can provide adequate protection [1]

Core Viewpoint - The animal health sector experienced a slight decline of 0.2% on November 24, with *ST Lvkang leading the drop [1][2] Market Performance - The Shanghai Composite Index closed at 3836.77, up 0.05% - The Shenzhen Component Index closed at 12585.08, up 0.37% [1] Individual Stock Performance - Notable gainers in the animal health sector included: - Shenlian Biological (688098) with a closing price of 9.57, up 2.57% on a trading volume of 55,100 shares and a turnover of 52.32 million yuan - Yongshun Biological (920729) at 8.95, up 1.59% with a trading volume of 15,900 shares and a turnover of 14.22 million yuan - Xianfeng Holdings (002141) at 3.98, up 1.53% with a trading volume of 694,200 shares and a turnover of 275 million yuan [1] Capital Flow Analysis - The animal health sector saw a net outflow of 35.49 million yuan from institutional investors, while retail investors contributed a net inflow of 31.36 million yuan [2][3] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [3] Stock-Specific Capital Flow - Key stocks with significant capital flow include: - Dayu Biological (920970) with a net inflow of 1.55 million yuan from institutional investors - Pulaike (603566) with a net inflow of 0.99 million yuan from institutional investors - Shenlian Biological (688098) faced a net outflow of 2.88 million yuan from institutional investors [3]

Core Insights - The Chinese pet industry has experienced unprecedented growth since the 21st century, transitioning from viewing pets as mere tools for guarding to recognizing them as essential emotional companions and family members [1][9] - The pet service sector has diversified significantly, encompassing medical, grooming, boarding, and training services to meet the evolving needs of pet owners [1][9] - The market for pet services in China is projected to grow from 34.034 billion yuan in 2015 to 104.47 billion yuan in 2024, with a compound annual growth rate (CAGR) of 13% [1][10] Pet Service Industry Overview - The pet industry includes all activities related to pets, such as breeding, trading, and providing goods and services like pet food, supplies, and services [3] - Pet services are defined as non-physical consumption services for pets and their owners, covering a wide range of offerings from grooming and medical care to training and insurance [3] Market Growth and Trends - The number of urban pets in China is expected to rise from 87.46 million in 2017 to 124.11 million by 2024, with a CAGR of 5.13% [5] - The pet consumption market in China is anticipated to expand from 97.8 billion yuan in 2015 to 300.2 billion yuan in 2024, with a CAGR of 13.27% [8] - In 2024, pet food is projected to account for 52.8% of the market, while pet services will represent 34.8% [8] Industry Development History - The establishment of the China Small Animal Protection Association in 1992 marked the beginning of the pet industry in China, promoting the concept of pets as companions [5] - Over the past thirty years, the pet service industry has evolved from basic breeding and trading to a comprehensive service model covering the entire lifecycle of pets [5][6] Industry Structure and Key Players - The pet service industry features a diverse competitive landscape, with key players in medical services including New Ruipeng and Ruipai, while grooming and boarding services are dominated by regional brands like Baozaiwu and Paiduo [10] - The market remains fragmented, with opportunities for growth through service extension, technological empowerment, and brand building [10] Future Trends in Pet Services - The industry is expected to embrace intelligent technology, integrating smart wearables and online platforms for enhanced pet health management and service efficiency [12] - Services will increasingly focus on emotional value and personalized experiences, such as customized training and memorial services for pets [13] - The service model will diversify, combining online and offline experiences, with O2O platforms and community-based services enhancing user engagement [14]

Core Viewpoint - The animal health sector experienced a slight decline of 0.31% on November 19, with Xianfeng Holdings leading the losses, while the Shanghai Composite Index rose by 0.18% to close at 3946.74 [1]. Group 1: Market Performance - The animal health sector's individual stock performance varied, with notable gainers including Qudongli (up 3.98% to 10.71) and ST Lvkang (up 3.80% to 46.40) [1]. - Conversely, several stocks faced declines, such as Jinhai Biological (down 0.96% to 6.19) and Shunlian Biological (down 1.08% to 10.12) [1][2]. Group 2: Trading Volume and Capital Flow - The total trading volume for the animal health sector was significant, with Qudongli achieving a volume of 34,000 hands and a transaction value of approximately 35.9 million yuan [1]. - The sector saw a net outflow of 49.13 million yuan from institutional investors, while retail investors contributed a net inflow of 548.09 million yuan [2]. Group 3: Individual Stock Capital Flow - Among individual stocks, Shengong Holdings experienced a net outflow of 31.56 million yuan from retail investors, while Biotech Holdings saw a net inflow of 555.72 million yuan from retail investors [3]. - The stock with the highest net inflow from retail investors was Biotech Holdings, with 555.72 million yuan, while the largest net outflow was from Yongshun Biological, totaling 408.61 million yuan [3].